source
- Mass. governor makes pre-election pitch to biotechs amid warning early-stage start-ups are 'dying'It may have seemed like an ordinary Wednesday afternoon at MassBio’s headquarters in Technology Square, but the black SUV parked outside was a telltale sign that the Cambridge, Massachusetts-based…Fierce Biotech · 16h ago↗ source
- Inhibrx’s OX40 agonist plus Keytruda shows 48% response rate, beating Keytruda alone in head and neck cancer Phase 2Inhibrx reported results from its Phase 2 HexAgon trial evaluating INBRX-106, an OX40 receptor agonist, combined with Merck’s Keytruda in patients with treatment‑naïve, PD‑L1‑positive metastatic or…